ARTICLES, BOOKS, SCIENTIFIC PAPERS


Chaussivert, J. and M. Blackman (1987), Louis Pasteur and the Pasteur Institute in Australia, Occasion Monograph No 1, University of New South Wales, 4–5 September.


Krayenbühl, C. and T. Rosenberg (1946), ‘Crystalline Protamine Insulin’, *Reports of the Steno Memorial Hospital*, 1, 60–73.

Kronstein, H. (1943), ‘The Dynamics of German Cartels and Patents. II’, 
The University of Chicago Law Review, 10 (1), 49–69.
Columbia Law Review, 52 (8), 983–1002.
Kronstein, H. and I. Till (1947), ‘A Reevaluation of the International 
Krueger, A.O. (1999), ‘Are Preferential Trading Arrangements Trade-
liberalizing or Protectionist?’, The Journal of Economic Perspectives, 13 
(4), 105–24.
and Pharmaceutical Drug Policies in Developing Countries’, International 
Lartigue, C. et al. (2007), ‘Genome Transplantation in Bacteria: Changing 
One Species to Another’, Science, New Series, 317 (5838), 362–638.
and Society’, Science, New Series, 166 (3910), 1227–33.
Law, S.D. (1870), Copyright and Patent Laws of the United States, 1790 to 
Technology Review, 27, 22–34.
Perspective’, Academic Medicine, 77 (12), 1388–91.
Law and Economics, 38, 463–95.
Li, A. (2003), J.B. Collip and the Development of Medical Research in 
Canada (Montreal; Canada: McGill-Queen’s University Press).
Liebenau, J. (1987), ‘The British Success with Penicillin’, Social Studies of 
Science, 17 (1), 69–86.
Lipinski, T.A. and J.J. Britz (2000), ‘Rethinking the Ownership of 
Information in the 21st Century: Ethical Implications’, Ethics and 
Information Technology, 2, 49–71.


Managing Intellectual Property (2007), ‘Why Thailand is at the centre of a patent storm’ (March).


Bibliography


Bibliography


### REPORTS

#### Australia

National Health & Medical Research Council (1993), *Report on the Epidemiology, Natural History and Control of Hepatitis C*.

#### Denmark


#### European Union


European Commission’s Directorate-General for Internal Market (2004), *Study on Evaluating the Knowledge Economy: What are Patents Actually Worth?*


European Commission’s Joint Research Centre (2007), *Consequences, Opportunities and Challenges of Modern Biotechnology for Europe*. 

**India**


**United Kingdom**


Board of Trade, K.R. Swan (1945), *Patents and Designs Acts, First Interim Report of the Departmental Committee* [Cmd 6618].


Committee of Inquiry, Lord Sainsbury (1967), *Relationship of the Pharmaceutical Industry with the National Health Services* [Cmd 3410].


Department of Trade (1975), *Patent Law Reform* [Cmd 6000].

House of Lords Select Committee on The European Communities (1994), *Patent Protection For Biotechnological Inventions.*


Prime Minister (1983), *Intellectual Property Rights and Innovation* [Cmd 9117].


**United States of America**


**NGOs**

Consumers International (2007), *Drugs, Doctors and Dinners, How drug companies influence health on the developing world*.
Bibliography


**UN Agencies**


**Others**

Consumers International (2007), *Drugs, Doctors and Dinners, How drug companies influence health in the developing world*.


Price Waterhouse Coopers (2007), *Pharma 2020: The Vision: which Path will you Take?*


**PATENT APPLICATIONS AND PATENTS**

**Australia**

AU 624, 105 (Effective from 18 November 1988), *NANBV diagnostics and vaccines*.

**European Patents**


EP 0,032,134 ((15 August 1984), *DNA sequences, recombinant DNA molecules and processes for producing human interferon-alpha like polypeptides*.


EP 0,083,286 (7 March 1990), *Modified vaccina virus and methods for making and using the same*.

EP 0,093,619 (13 September 1989), *Human tissue plasminogen activator, pharmaceutical compositions containing it, processes for making it, and DNA and transformed cell intermediates thereof*.

EP 0,096,430 (10 January 1990), *Cloning system for Kluyveromyces species*.
EP 0,112,149 (10 April 1991), Molecular cloning and characterization of a further gene sequence coding for human relaxin.
EP 0,148,605 (25 July 1990), Production of erythropoietin.
EP 0,159,418 (9 May 1990), A process for the incorporation of foreign DNA into the genome of monocotyledonous plants.
EP 0,182,442 (11 July 1990), Recombinant DNA molecules and their method of production.
EP 0,209,539 (20 May 1992), Homogeneous Erythropoietin.
EP 0,236,145 (27 March 1991), Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor. [sic]
EP 0,318,216 (15 December 1993), NANBV diagnostics.
EP 0,411,678 (8 January 1992), Method for the production of erythropoietin.
EP 0,414,475 (10 December 1997), Methods for culturing HCV in B- or T-lymphocyte cell lines.
EP 0,450,931 (9 October 1991), Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies.
EP 0,543,924 (18 June 1997), NANBV diagnostics: polynucleotides useful for screening for hepatitis c virus.
EP 0,693,687 (28 July 1999), Combinations of hepatitis c virus (HCV) antigens for use in immunoassays for anti-HCV antibodies.
EP 0,699,754 (10 January 2001), Method for diagnosing a predisposition for breast and ovarian cancer.
EP 0,705,902 (28 November 2001), 17q-linked breast and ovarian cancer susceptibility gene.
EP 0,705,903 (23 May 2001), 17q-linked breast and ovarian cancer susceptibility gene.
EP 0,785,216 (8 January 2003), Chromosome 13-linked breast cancer susceptibility gene BRCA 2.
EP 0,858,467 (11 February 2004), Materials and methods relating to the identification and sequencing of the BRCA 2 cancer susceptibility gene and uses thereof.

**United Kingdom Patents**

GB 0,747,779 (11 April 1956), A new antibiotic tetracycline and salts thereof.
GB 0,796,493 (11 June 1958), Production of tetracycline by fermentation.
GB 0,828,911 (24 February 1960), Improvements in or relating to the purification and separation of tetracycline.
GB 0,934,853 (21 August 1963), Production of the antibiotic porfiromycin.
GB 2,212,511 (22 January 1992), Hepatitis C Virus.
GB 2,257,784 (4 January 1995), Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies.

United States Patents

US 0,095,465 (5 October 1869), ‘Improved process of preparing alizarine. (Reissued as: US 4,321 (4 April 1871) Improvement in dyes or coloring matter from anthracene).
US 0,135,245 (28 January 1873), Improvement in Brewing Beer and Ale.
US 0,141,092 (22 July 1873), Improvement in the Manufacture of Beer and Yeast.
US 0,153,536 (28 July 1874), Improvement in the preparation of coloring matters from anthracene.
US 0,644,077 (27 February 1900), Acety Salicylic Acid.
US 1,018,502 (27 February 1912), Incandescent Bodies For Electric Lamps.
US 1,082,933 (30 December 1913), Tungsten and methods of Making the same for use as Filaments of Incandescent Electric Lamps and for other purposes.
US 1,469,994 (9 October 1923), Extract Obtainable from the Mammalian Pancreas or from the Related Glands in Fishes, Useful in the Treatment of Diabetes Mellitus, and a Method of Preparing It.
US 1,520,673 (23 December 1924), Purified Antidiabetic Product and Process of Making It.
US 2,699,054 (11 January 1955), Tetracycline.
US 2,776,243 (1 January 1957), Process for production of tetracycline.
US 2,998,352 (29 August 1961), Production of tetracyclines.
US 3,591,574 (6 July 1971), Tri-N-Phenylglycyl Derivatives of Insulin.
US 3,813,316 (28 May 1974), Microorganisms having multiple compatible degradative energy-generating plasmids and preparation thereof.
US 3,903,068 (2 September 1975), Facile synthesis of human insulin by modification of porcine insulin.
US 4,007,196 (8 February 1977), 4-Phenylpiperidine compounds.
US 4,029,642 (14 June 1977), Process for the manufacture of human insulin.
US 4,190,495 (26 February 1980), Modified microorganisms and method of preparing and using same.
US 4,320,196 (16 March 1982), Semi-synthesis of human insulin.
US 4,332,892 (1 June 1982), Protein synthesis.
US 4,342,832 (3 August 1982), Method of constructing a replicable cloning vehicle having quasi-synthetic genes.
US 4,356,270 (26 October 1982), Recombinant DNA cloning vehicle.
US 4,363,877 (14 December 1982), Recombinant DNA transfer vectors.
US 4,399,216 (16 August 1983), Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials.
US 4,421,685 (20 December 1983), Process for producing an insulin.
US 4,431,740 (14 February 1984), DNA Transfer vector and transformed microorganism containing human proinsulin and pre-proinsulin genes.
US 4,440,859 (3 April 1984), Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms.
US 4,571,421 (18 February 1986), Mammalian gene for microbial expression.
US 4,634,665 (6 January 1987), Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials.
US H245 (7 April 1987), Plasmid for producing human insulin.
US 4,652,525 (24 March 1987), Recombinant bacterial plasmids containing the coding sequences of insulin genes.
US 4,674,204 (23 June 1987), Shock absorbing innersole and method of preparing same.
US 4,677,195 (30 June 1987), Method for the purification of erythropoietin and erythropoietin compositions.
US 4,703,008 (27 October 1987), DNA sequences encoding erythropoietin.
US 4,704,362 (3 November 1987), *Recombinant cloning vehicle microbial polypeptide expression.*


US 4,898,830 (6 February 1990), *Human growth hormone DNA.*


US 5,179,017 (12 January 1993), *Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials.*


US 5,221,619 (22 June 1993), *Method and means for microbial polypeptide expression.*


US 5,405,942, (11 April 1995), *Prepro insulin-like growth factors I and II.*

US 5,424,199 (13 June 1995), *Human growth hormone.*


US 5,618,698 (8 April 1997), *Production of erythropoietin.*

US 5,621,080 (15 April 1997), *Production of erythropoietin.*

US 5,654,155 (5 August 1997), *Consensus sequence of the human BRCA 1 gene.*


US 5,710,001 (20 January 1998), *17q-linked breast and ovarian cancer susceptibility gene.*


US 5,863,719 (26 January 1999), Methods for detecting hepatitis C virus using polynucleotides specific for same.
US 5,968,502 (19 October 1999), Protein production and protein delivery.
US 6,027,729 (22 February 2000), NANBV Diagnostics and vaccines.
US 6,037,351 (14 March 2000), Method of inhibiting hepatitis B virus.
US 6,045,997 (4 April 2000), Materials and methods relating to the identification and sequencing of the BRCA 2 cancer susceptibility gene and uses thereof.
US 6,048,524 (11 April 2000), In vivo production and delivery of erythropoietin for gene therapy.
US 6,054,561 (25 April 2000), Antigen-binding sites of antibody molecules specific for cancer antigens.
US 6,074,816 (13 June 2000), NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus.
US 6,113,944 (5 September 2000), Paroxetine tablets and process to prepare them.
US 6,331,414 (18 December 2001), Preparation of human IGF via recombinant DNA technology.
US 6,331,415 (18 December 2001), Methods of producing immunoglobulins, vectors and transformed host cells for use therein.
US 6,930,170 (16 August 2005), PRO1184 polypeptides.
US 6,989,265 (24 January 2006), Bacteria with reduced genome.
US 7,045,346 (16 May 2006), Nucleic acid constructs useful for glucose regulated production of human insulin in somatic cell lines.
US 7,250,497 (31 July 2007), Large deletions in human BRCA 1 gene and use thereof.

United States Patent Applications

US 20030170663 (11 September 2003), Nucleotide sequence of the Mycoplasma genitalium genome, fragments thereof, and uses thereof.

US 20050191316 (1 September 2005), *Neisseria genomic sequences and methods of their use.*

US 20070026021 (1 February 2007), *Neisseria meningitidis antigens and compositions.*

US 20070037165 (15 February 2007), *Polymorphisms in known genes associated with human disease, methods of detection and uses thereof.*


US 20070264688 (15 November 2007), *Synthetic genomes.*

US 20070269862 (22 November 2007), *Installation of genomes or partial genomes into cells or cell-like systems.*


